PBMCs from 35 CLL patients (>90% CD19+, CD5+ B cells) and 10 healthy donors were treated with increasing concentrations of deguelin (0–10 μM), and cell viability was evaluated at 48 h by Annexin V/PI staining and flow cytometry. The gene discussed is CD5; the disease is B-cell chronic lymphocytic leukemia.